MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.45
-0.19
-1.63%
After Hours: 11.45 0 0.00% 16:00 01/24 EST
OPEN
11.66
PREV CLOSE
11.64
HIGH
11.80
LOW
11.26
VOLUME
673.53K
TURNOVER
--
52 WEEK HIGH
16.38
52 WEEK LOW
2.900
MARKET CAP
739.53M
P/E (TTM)
-11.8912
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADVM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADVM News

  • Adverum Biotechnologies Option Alert: Feb 21 $15 Calls at the Ask: 1046 @ $0.801 vs 84 OI; Earnings 3/4 After Close [est] Ref=$10.42
  • Benzinga.01/13 18:49
  • PiperJaffray Reiterates Overweight on Adverum Biotechnologies, Raises Price Target to $20
  • Benzinga.01/13 12:41
  • Adverum Biotechnologies Announces OPTIC Phase 1 Trial Progressing With Plans to Complete Patient Dosing in Cohort Three, Begin Enrollment in Cohort Four in Q1 2020
  • Benzinga.01/13 00:14
  • Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook
  • GlobeNewswire.01/12 23:00

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ADVM

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
More

Webull offers Adverum Biotechnologies Inc (ADVM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.